Atorvastatin - Lipid Disorders (Paperback, 2nd Revised edition)

Drugs in Context is an independent, peer reviewed and practice orientated review of all the significant data on a specific drug, placed in the context of the disease and clinical practice setting. Atorvastatin; Editorial: Within the space of a decade, the treatment of raised serum cholesterol has moved from the province of a few specialists to the very heart of everyday medical practice. Disease Overview: Raised cholesterol, in particular low density lipoprotein cholesterol (LDL-C), appears to be a pivotal risk factor in the development of coronary heart disease (CHD). Drug Review: More patients receiving atorvastatin at its initial dose (53 per cent) achieved their NCEP target LDL-C levels than patients receiving initial doses of cent) or fluvastatin (15 per cent). Improving Practice: The burden of cardiovascular disease in the UK is large and is likely to increase as the population ages. At current rates, nearly half the population will die from a cardiovascular cause and so the problem impacts on all healthcare professionals.